DrugPatentWatch Database Preview
Drugs in Development Information for CUDC-907
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug CUDC-907?
CUDC-907 is an investigational drug.
There have been 13 clinical trials for CUDC-907.
The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Head and Neck Neoplasms, and Lymphoma, B-Cell. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and Pacific Pediatric Neuro-Oncology Consortium.
There are ten US patents protecting this investigational drug and one hundred and six international patents.
Summary for CUDC-907
| US Patents | 10 |
| International Patents | 106 |
| US Patent Applications | 28 |
| WIPO Patent Applications | 12 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2016-01-01) |
| Vendors | 49 |
Recent Clinical Trials for CUDC-907
| Title | Sponsor | Phase |
|---|---|---|
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Cannonball Kids' Cancer Foundation | Early Phase 1 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Curis, Inc. | Early Phase 1 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Pacific Pediatric Neuro-Oncology Consortium | Early Phase 1 |
Clinical Trial Summary for CUDC-907
Top disease conditions for CUDC-907
Top clinical trial sponsors for CUDC-907
US Patents for CUDC-907
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | System and method of producing volatile organic compounds from fungi | Start Trial | |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CUDC-907
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CUDC-907 | Australia | 2012236367 | 2031-04-01 | Start Trial |
| CUDC-907 | Brazil | 112013025340 | 2031-04-01 | Start Trial |
| CUDC-907 | Canada | 2830822 | 2031-04-01 | Start Trial |
| CUDC-907 | Chile | 2013002823 | 2031-04-01 | Start Trial |
| CUDC-907 | China | 103582483 | 2031-04-01 | Start Trial |
| CUDC-907 | China | 105461736 | 2031-04-01 | Start Trial |
| CUDC-907 | Cyprus | 1117785 | 2031-04-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
